Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.
- Bill Number
- H.Res. 685
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-09: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-09-27T08:06:01Z
AI-Generated Summary
Purpose
The purpose of H. Res. 685 is to express congressional support for adding routine blood testing for antiphospholipid syndrome (APS) to standard prenatal screening and to urge medical groups to revise their guidelines to make this testing common practice for all pregnant individuals.
Key Provisions
- States support for APS testing as a standard part of prenatal screening.
- Calls on professional medical associations and guideline-setting bodies to update their recommendations to include APS testing routinely, rather than only after specific pregnancy losses.
Significant Changes to Existing Law
This resolution introduces no changes to existing law. It is a non-binding House resolution that does not amend statutes or require any federal action.
Potential Impacts
- Government agencies: Little to no direct effect, as the measure does not direct agencies to implement or fund new programs.
- Citizens: Could encourage broader screening that detects APS earlier, allowing treatment with blood thinners and potentially lowering rates of miscarriages, stillbirths, and related pregnancy complications.
- International relations: No impact.
Main Stakeholders
- Pregnant individuals and families seeking prenatal care.
- Healthcare providers who conduct screenings.
- Professional medical associations responsible for setting prenatal guidelines.
Notable Implications
The resolution points to a possible shortfall in current medical recommendations by noting that APS causes about 15 percent of repeated pregnancy losses yet is not routinely tested. It carries political weight as an effort to influence medical practice through congressional advocacy but presents no constitutional or legal conflicts.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (8)
Rep. Kamlager-Dove, Sydney [D-CA-37], Rep. Kim, Young [R-CA-40], Rep. Pettersen, Brittany [D-CO-7], Rep. Hinson, Ashley [R-IA-2], Rep. Adams, Alma S. [D-NC-12], Rep. Cherfilus-McCormick, Sheila [D-FL-20], Rep. Landsman, Greg [D-OH-1], Rep. Luna, Anna Paulina [R-FL-13]
Recent Actions
- 2025-09-09: Referred to the House Committee on Energy and Commerce.
- 2025-09-09: Submitted in House
- 2025-09-09: Submitted in House
Bill Versions
- Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes. — issued 2025-09-09 — PDF (2 pages)